News items Chemotherapie gericht losklikken leidt tot goede resultaten in muizen

4 May 2018

Tagworks Pharmaceuticals, based at Radboud university medical center, has developed a new technique for the targeted delivery of chemotherapy for tumors in cases where this was previously very difficult. By way of the controlled ‘click-to-release’ of the chemotherapy drug from its tumor-binding carrier, the chemotherapy can be activated at the right location. The company is publishing the results of studies in mice that have been treated with this method in Nature Communications.

Antibody Drug Conjugates (ADCs) are relatively new anti-cancer drugs. They consist of an antibody to which a cell-killing molecule (chemotherapy) is attached. Antibodies can recognize and bind to certain receptors (the ‘hands’ on the outside of a cell) in a very targeted way. The antibody in an ADC is designed to adhere exclusively to receptors that are characteristic of a tumor cell. The chemotherapy drug is not released until the receptor has brought the entire structure into the cell, and then the chemotherapy drug can do its job.
 
ADCs are currently already used for the treatment of lymphoma and metastatic breast cancer. “These ADCs work very well,” says Marc Robillard of Tagworks Pharmaceuticals, a company based at Radboud university medical center. “But for many other tumors, including colon cancer and ovarian cancer, this method is not yet applicable. The problem is that there are not many suitable cancer-specific receptors that automatically drag such an ADC into the cell, and if the ADC gets stuck on the outside, the chemotherapy drug will not be released and therefore can’t do its job.”
 
Chemotherapy drug released
It is vital to ensure that the chemotherapy drug is also released if the ADC remains on the outside of the tumor cells. To achieve this objective, Tagworks has designed a smart variant of the ADCs. The ADC is injected and then binds to the receptors on the tumor cells. After a day or two, the tumor is filled with these ADCs. So far, this is nothing new. Robillard: “Our innovation is that we inject a second component that ‘click-releases’ the chemotherapy drug from the ADC. As a result, a large quantity of chemotherapy is released very quickly, attacking the tumor. This method will hopefully enable us to treat many more types of cancer.”
 
Effective in mice
The first results of this new ‘click-to-release’ method in mice have now been published in Nature Communications. Robillard: “We studied ovarian cancer and an aggressive form of colon cancer. In both cases we observed a pronounced anticancer effect. For control purposes, we also applied a ‘traditional’ ADC, i.e., without the second component that causes the chemotherapy drug to release, but this approach had no therapeutic effect  in these forms of cancer.”
 
Cooperation
In Nijmegen, Tagworks collaborates with a variety of research groups, Technology Centers and Research Facilities, which have been specifically set up for cooperation with the business community, including the Radboudumc Technology Center for Mass Spectrometry. In addition, Tagworks cooperates with specialized small and medium-sized enterprises that are also co-authors of the publication. According to Robillard, this illustrates the importance of cooperation. “Developing new drugs for cancer is very complex and requires the expertise of specialists. No party can do this by itself. I believe this result is a fine example of how you can maximize the innovative power of small and medium-sized businesses by joining forces and connecting with the advanced facilities and high-quality knowledge of institutions such as Radboud university medical center and Radboud University.” 

More information


Marcel Wortel

information officer

(024) 81 87389

Pieter Lomans

information officer

(024) 81 87012

Related news items


Radium 223-mediated zonal cytotoxicity of prostate cancer in bone

21 January 2019

In preclinical prostate carcinoma in the bone, Rad-223 eradicated effectively micro-tumors but macro-tumors persisted and expanded. The data point to application of Rad-223 in secondary prevention of early bone-metastatic disease and regimens co-targeting the tumor core.

read more

COPAL reveals remodeling of mitochondrial protein complexes in Barth syndrome

21 January 2019

Martijn Huijnen, theme Mitochondrial diseases, and colleagues developed COmplexome Profiling ALignment (COPAL) to systematically asses the effect of Barth syndome on mitochondrial protein complexes. They published their findings in Bioinformatics.

read more

Adjunct Professorship awarded to Barbara Franke at the Goethe University in Frankfurt am Main

21 January 2019

Barbara Franke is awarded an honorary Adjunct Professorship at the Goethe University in Frankfurt am Main in Germany.

read more

Ignacio Malagon, first professor of Pediatric Anaesthesiology in the Netherlands

21 January 2019

Ignacio Malagon has been appointed professor of Pediatric Anaesthesiology at Radboud University / Radboud university medical center with effect from 1 January 2019. He is the first professor in this field in the Netherlands.

read more

Two papers on molecular mechanisms of GFI1B in inherited bleeding syndromes in Haematologica

21 January 2019

Rinske van Oorschot from the Van der Reijden group, theme Cancer development and immune defense, has published two papers on the transcription factor GFI1B in Haematologica.

read more

Blog: Species Differences The Elephant in the Room

17 January 2019

Read the blog of Merel Ritskes-Hoitinga in the New England anti-vivisection society (neavs) based on a paper published in the Journal of Translational Medicine.

read more
  • Go to